Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which of the following drugs used in gout acts by converting uric acid into allantoin?

Rasburicase. **Explanation:** **Correct Answer: D. Rasburicase** Rasburicase is a recombinant form of the enzyme **urate oxidase**. Humans lack this enzyme due to an evolutionary mutation. It works by catalyzing the oxidation of uric acid into **allantoin**, a highly water-soluble metabolite that is easily excreted by the kidneys. Because it works directly on existing uric acid in the blood, it acts rapidly and is primarily used to prevent and treat hyperuricemia in **Tumor Lysis Syndrome**. **Why other options are incorrect:** * **A. Colchicine:** It is an anti-inflammatory drug that inhibits **microtubule polymerization** by binding to tubulin. It prevents neutrophil migration and degranulation; it has no effect on uric acid levels. * **B. Allopurinol:** It is a hypuricemic agent that acts as a **xanthine oxidase inhibitor**. It prevents the *synthesis* of uric acid from hypoxanthine and xanthine but does not break down existing uric acid. * **C. Probenecid:** It is a **uricosuric** drug. It inhibits the URAT-1 transporter in the proximal tubule, thereby decreasing the reabsorption of uric acid and increasing its renal excretion. **High-Yield Clinical Pearls for NEET-PG:** * **Pegloticase:** A pegylated recombinant urate oxidase used for chronic refractory gout. * **Contraindication:** Rasburicase and Pegloticase are contraindicated in **G6PD deficiency** because the breakdown of uric acid produces hydrogen peroxide, which can trigger hemolysis. * **Drug of Choice:** Allopurinol is the DOC for chronic gout, while NSAIDs (or Colchicine) are the DOC for acute gouty attacks.

Q: Which of the following are features of opioid withdrawal?

Abdominal cramps, vomiting, insomnia. Opioid withdrawal occurs due to the sudden cessation or reduction of opioid use in a physically dependent individual, or the administration of an opioid antagonist (e.g., Naloxone) [1]. The underlying mechanism is **rebound hyperactivity of the autonomic nervous system**, particularly the sympathetic system, as the body attempts to compensate for the absence of the chronic CNS depressant effect of opioids [1]. **Why Option B is Correct:** Opioids typically cause constipation, sedation, and miosis [3]. Withdrawal presents as the "polar opposite" of these effects: * **Gastrointestinal:** Increased motility leads to **abdominal cramps**, nausea, and **vomiting** [2]. * **CNS:** Hyper-excitability leads to **insomnia**, anxiety, and restlessness [2]. * **Autonomic:** Mydriasis, rhinorrhea, lacrimation, and piloerection ("cold turkey") [2]. **Why Other Options are Incorrect:** * **Option A & D:** Constipation and bradycardia are features of **opioid toxicity (overdose)**, not withdrawal [3]. In withdrawal, patients experience diarrhea and tachycardia [2]. * **Option C:** While vomiting and restlessness occur, **hyperthermia** is less characteristic than sweating and chills. Option B provides a more classic triad of withdrawal symptoms frequently tested in exams. **High-Yield Clinical Pearls for NEET-PG:** 1. **Objective Sign:** **Piloerection** (goosebumps) is a pathognomonic sign of severe opioid withdrawal [2]. 2. **Pupils:** Opioid overdose causes "pin-point pupils" (miosis), whereas withdrawal causes **mydriasis** (dilated pupils) [3]. 3. **Management:** * **Methadone or Buprenorphine** (Substitution therapy). * **Clonidine** (Alpha-2 agonist) is used to reduce sympathetic overactivity (tachycardia, hypertension). 4. **Severity:** While extremely distressing, opioid withdrawal is rarely life-threatening, unlike alcohol or benzodiazepine withdrawal (which can cause seizures).

Q: Which one of the following is the shortest acting intravenous analgesic?

Remifentanil. **Explanation:** The correct answer is **Remifentanil**. The primary factor determining the duration of action of these opioid analgesics is their metabolic pathway. Remifentanil is unique because it contains an **ester linkage**, making it susceptible to rapid hydrolysis by **non-specific plasma and tissue esterases**. Unlike other opioids, its metabolism is independent of hepatic or renal function. It has an ultra-short context-sensitive half-life (approximately 3–4 minutes) that remains constant regardless of the duration of infusion, allowing for rapid recovery. **Analysis of Incorrect Options:** * **Fentanyl:** A highly lipid-soluble opioid. While it has a rapid onset, its duration of action increases significantly with prolonged infusion due to redistribution and accumulation in adipose tissue (long context-sensitive half-life). * **Alfentanil:** Although it has a faster onset than fentanyl (due to a low pKa and high unionized fraction), its metabolism is hepatic (CYP3A4). It is shorter-acting than fentanyl but significantly longer-acting than remifentanil. * **Sufentanil:** The most potent opioid among the options. Like fentanyl, it is highly lipophilic and undergoes hepatic metabolism, resulting in a longer duration of action compared to remifentanil. **NEET-PG High-Yield Pearls:** * **Metabolism:** Remifentanil = Plasma esterases; Fentanyl/Alfentanil/Sufentanil = Hepatic (CYP450). * **Context-Sensitive Half-life:** This is the time required for the plasma concentration to decrease by 50% after stopping an infusion. Remifentanil has the shortest and most predictable context-sensitive half-life in clinical anesthesia. * **Clinical Use:** Remifentanil is ideal for procedures requiring intense analgesia with rapid emergence (e.g., neurosurgery or "total intravenous anesthesia" - TIVA).

Q: Which of the following drugs is a full agonist at opioid receptors, has excellent oral bioavailability, is equipotent to morphine, and has a longer duration of action with milder withdrawal symptoms on abrupt discontinuation?

Methadone. The correct answer is **Methadone**. This drug is a synthetic µ-opioid receptor agonist with unique pharmacokinetic properties that make it ideal for opioid detoxification and maintenance programs [1]. **Why Methadone is correct:** * **Bioavailability:** Unlike morphine, which undergoes extensive first-pass metabolism, methadone has excellent oral bioavailability (approx. 80%) [1]. * **Potency:** It is roughly equipotent to morphine in chronic dosing [1]. * **Duration of Action:** It has a very long half-life (15–40 hours), leading to a prolonged duration of action [2]. * **Withdrawal Profile:** Because of its long half-life, the withdrawal symptoms upon abrupt discontinuation are **milder but more prolonged** compared to the intense, short-lived withdrawal seen with morphine or heroin. **Why other options are incorrect:** * **Fentanyl:** It is significantly more potent than morphine (approx. 100x) and has a very short duration of action when given parenterally [2]. * **Hydromorphone:** While a potent full agonist, it has a shorter half-life and more intense withdrawal symptoms than methadone [2]. * **Nalbuphine:** This is a **mixed agonist-antagonist** (κ-agonist and µ-antagonist). It exhibits a

Q: Which of the following drugs acts by inhibiting granulocyte migration?

Colchicine. **Explanation:** **Colchicine** is the correct answer because its primary mechanism of action involves binding to **tubulin**, a structural protein. This binding inhibits microtubule polymerization, which is essential for various cellular functions. In the context of acute gout, colchicine disrupts the formation of the mitotic spindle and cytoskeleton in neutrophils. This leads to the **inhibition of granulocyte migration** (chemotaxis) into the inflamed joint and reduces the phagocytosis of urate crystals, thereby halting the inflammatory cascade. **Analysis of Incorrect Options:** * **Montelukast:** This is a **Leukotriene Receptor Antagonist (LTRA)** that selectively blocks the CysLT1 receptor. It is used in the management of asthma and allergic rhinitis, not for inhibiting granulocyte migration. * **Cromoglycate:** This is a **Mast Cell Stabilizer**. It prevents the degranulation of mast cells and the subsequent release of histamine and leukotrienes; it does not directly affect granulocyte chemotaxis. * **Allopurinol:** This is a **Xanthine Oxidase Inhibitor** used for the chronic management of gout (hypouricemic therapy). It reduces the synthesis of uric acid but has no direct anti-inflammatory or anti-migratory effect during an acute attack. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** While Colchicine is classic, **NSAIDs** (like Indomethacin) are currently the first-line treatment for acute gout due to the side-effect profile of colchicine. * **Toxicity:** The dose-limiting toxicity of Colchicine is **diarrhea** (gastrointestinal toxicity). * **Other Uses:** Colchicine is also used in Familial Mediterranean Fever (FMF), Behçet’s disease, and recurrent pericarditis. * **Contraindication:** It should be avoided in patients with severe renal or hepatic impairment.

Q: Secukinumab is:

Anti IL-17. **Explanation:** **Secukinumab** is a high-affinity recombinant human monoclonal antibody that selectively binds to and neutralizes **Interleukin-17A (IL-17A)**. IL-17 is a pro-inflammatory cytokine produced primarily by Th17 cells; it plays a critical role in the pathogenesis of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis by inducing the production of chemokines and mediators of tissue inflammation. **Analysis of Options:** * **Option A (Anti IL-1):** Drugs targeting IL-1 include **Anakinra** (IL-1 receptor antagonist), **Canakinumab**, and **Rilonacept**. These are primarily used in cryopyrin-associated periodic syndromes (CAPS) and refractory Rheumatoid Arthritis. * **Option B (Anti IL-6):** **Tocilizumab** and **Sarilumab** are the classic IL-6 receptor antagonists used in Rheumatoid Arthritis and Giant Cell Arteritis. * **Option C (Correct):** Secukinumab (along with Ixekizumab) targets IL-17A. Brodalumab is another related drug that targets the IL-17 receptor. * **Option D (Anti IL-23):** Drugs targeting the p40 subunit of IL-12/23 include **Ustekinumab**, while **Guselkumab** and **Risankizumab** specifically target IL-23. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. * **Side Effects:** Increased risk of infections (especially upper respiratory tract) and a notable association with **Mucocutaneous Candidiasis** (since IL-17 is essential for host defense against fungi). * **Contraindication:** It may exacerbate **Inflammatory Bowel Disease (IBD)**, so it should be avoided in patients with Crohn’s disease or Ulcerative Colitis.

Q: What is true about anaphylactoid reactions caused by NSAIDs?

COX-2 inhibitors are safe.. **Explanation:** The "anaphylactoid" reaction (pseudo-allergy) caused by NSAIDs is not a true Type-I IgE-mediated hypersensitivity. Instead, it is a **pharmacological phenomenon** resulting from the inhibition of the **COX-1 enzyme**. **Why Option B is Correct:** When COX-1 is inhibited, the metabolism of arachidonic acid is diverted toward the **5-Lipoxygenase (5-LOX) pathway**. This leads to an overproduction of **cysteinyl leukotrienes**, which cause potent bronchoconstriction, vasodilation, and angioedema. Since **Selective COX-2 inhibitors** (e.g., Celecoxib, Etoricoxib) do not inhibit COX-1 at therapeutic doses, they do not trigger this leukotriene shift. Therefore, they are considered safe alternatives for patients with NSAID-induced asthma or urticaria. **Analysis of Incorrect Options:** * **Option A:** Not all NSAIDs cause this in all patients; it specifically occurs in "aspirin-sensitive" individuals (often associated with Samter’s Triad). * **Option C:** These are **anaphylactoid**, not anaphylactic. They do not involve prior sensitization or IgE antibodies; they occur due to direct biochemical mediator release. * **Option D:** The reaction is **directly related** to the inhibition of COX-1. **High-Yield Clinical Pearls for NEET-PG:** * **Samter’s Triad (Aspirin-Exacerbated Respiratory Disease):** Consists of Asthma, Nasal polyposis, and Aspirin intolerance. * **Drug of Choice:** For a patient with a history of NSAID-induced bronchospasm needing an analgesic, **Selective COX-2 inhibitors** or **Paracetamol** (in low doses, as it is a weak COX-1 inhibitor) are the preferred choices. * **Mechanism:** Shunting of arachidonic acid to the LOX pathway.

Q: Morphine is contraindicated in all of the following conditions except?

Pulmonary edema. **Explanation:** **Correct Answer: A. Pulmonary edema** Morphine is not only indicated but is a **drug of choice** in the management of acute Left Ventricular Failure (LVF) and **Acute Pulmonary Edema**. Its therapeutic benefit is derived from its **venodilatory effect** (mediated by histamine release and reduced sympathetic tone), which increases venous capacitance. This reduces venous return (preload) and decreases pulmonary capillary pressure, providing rapid symptomatic relief from "air hunger." **Why the other options are contraindications:** * **B & C (Emphysema and Bronchial Asthma):** Morphine is a potent **respiratory depressant**. It reduces the sensitivity of the respiratory center to $CO_2$. In COPD/Emphysema, where the respiratory drive is already compromised, it can lead to fatal respiratory failure. In Asthma, morphine-induced **histamine release** can trigger bronchospasm, worsening the condition. * **D (Head Injury):** Morphine is strictly contraindicated in head injuries for two reasons: 1. It causes respiratory depression, leading to $CO_2$ retention. $CO_2$ is a potent vasodilator that **increases intracranial pressure (ICP)**, risking brain herniation. 2. It causes **miosis** (pin-point pupils), which interferes with the neurological monitoring of pupillary responses (a key sign of clinical worsening). **High-Yield Clinical Pearls for NEET-PG:** * **Biliary Colic:** Morphine is generally avoided because it causes constriction of the **Sphincter of Oddi**, potentially worsening the pain. Pethidine is often preferred. * **Antidote:** In case of morphine overdose (triad of miosis, coma, and respiratory depression), the specific antagonist is **Naloxone**. * **Mnemonic for Contraindications:** **"HEAD"** – **H**ead injury, **E**lderly/Endocrine (Myxedema), **A**sthma/COPD, **D**elivery (causes neonatal respiratory depression).

Q: Which of the following drugs is NOT used for analgesia in a patient with head injury?

Morphine. **Explanation:** The correct answer is **Morphine**. In patients with head injuries, opioids like Morphine are strictly contraindicated due to several critical physiological interactions: 1. **Respiratory Depression & ICP:** Morphine causes respiratory depression, leading to CO₂ retention (hypercapnia). CO₂ is a potent cerebral vasodilator; vasodilation increases cerebral blood volume, which further elevates **Intracranial Pressure (ICP)**, potentially leading to brain herniation. 2. **Miosis:** Morphine causes pupillary constriction (pin-point pupils). This masks the pupillary changes (like dilation) that clinicians use to monitor for neurological worsening or transtentorial herniation. 3. **Sedation:** It induces drowsiness and mental clouding, making it impossible to accurately assess the patient’s Glasgow Coma Scale (GCS) score. 4. **Emetic Effect:** It can cause vomiting, which further spikes ICP. **Why other options are incorrect:** * **NSAIDs (e.g., Ibuprofen) & Rofecoxib (COX-2 Inhibitor):** These do not cause respiratory depression or pupillary changes. While non-selective NSAIDs are sometimes avoided if there is a high risk of intracranial hemorrhage (due to anti-platelet effects), they do not carry the same absolute contraindication as opioids regarding ICP monitoring. * **Acetaminophen (Paracetamol):** This is the preferred analgesic in head injury cases as it provides effective pain relief without affecting the respiratory drive, pupil size, or neurological status. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice for pain in head injury:** Acetaminophen (Paracetamol). * **Opioid of choice if necessary:** Fentanyl is sometimes preferred over Morphine in ICU settings due to its shorter half-life, but generally, opioids are avoided. * **Triad of Opioid Poisoning:** Miosis, Respiratory Depression, and Coma.

Q: Which of the following is a selective COX-2 inhibitor?

Celecoxib. **Explanation:**1. Why Celecoxib is correct:Non-Steroidal Anti-inflammatory Drugs (NSAIDs) are classified based on their selectivity for Cyclooxygenase (COX) enzymes. **Celecoxib** is a diaryl-substituted pyrazole that specifically binds to the distinct side pocket of the **COX-2** isoenzyme [1]. Unlike non-selective NSAIDs, it does not inhibit COX-1 at therapeutic concentrations. This selectivity preserves the cytoprotective prostaglandins in the gastric mucosa, significantly reducing the risk of peptic ulcers and GI bleeding [1, 2].2. Why other options are incorrect:* **Indomethacin:** It is a potent, **non-selective COX inhibitor** (acetic acid derivative). It is highly effective but associated with a high incidence of GI side effects and frontal headaches.* **Naproxen:** It is a propionic acid derivative and a **non-selective COX inhibitor**. It is often preferred in patients with high cardiovascular risk because it has a more favorable profile regarding platelet inhibition compared to other NSAIDs.* **Option D:** Incorrect because only Celecoxib exhibits COX-2 selectivity.3. NEET-PG High-Yield Clinical Pearls:* **The "Sulfa" Connection:** Celecoxib contains a sulfonamide moiety; use with caution in patients with known **sulfa allergies**.* **Cardiovascular Risk:** While selective COX-2 inhibitors (Coxibs) are "gastric-friendly," they lack anti-platelet activity (as platelets only express COX-1). This creates a pro-thrombotic state, increasing the risk of **Myocardial Infarction and Stroke** [1, 2].* **Etoricoxib:** This is the most COX-2 selective agent available globally [1].* **Therapeutic Use:** Celecoxib is often used in osteoarthritis, rheumatoid arthritis, and familial adenomatous polyposis (FAP) [1].

Question 1

Which of the following drugs used in gout acts by converting uric acid into allantoin?

Accepted Answer

Rasburicase

Answer

Colchicine

Answer

Allopurinol

Answer

Probenecid

Question 2

Which of the following are features of opioid withdrawal?

Accepted Answer

Abdominal cramps, vomiting, insomnia

Answer

Constipation, bradycardia, coma

Answer

Hyperthermia, vomiting, restlessness

Answer

Hypothermia, nausea, constipation

Question 3

Which one of the following is the shortest acting intravenous analgesic?

Accepted Answer

Remifentanil

Answer

Fentanyl

Answer

Alfentanil

Answer

Sufentanil

Question 4

Which of the following drugs is a full agonist at opioid receptors, has excellent oral bioavailability, is equipotent to morphine, and has a longer duration of action with milder withdrawal symptoms on abrupt discontinuation?

Accepted Answer

Methadone

Answer

Fentanyl

Answer

Hydromorphone

Answer

Nalbuphine

Question 5

Which of the following drugs acts by inhibiting granulocyte migration?

Accepted Answer

Colchicine

Answer

Montelukast

Answer

Cromoglycate

Answer

Allopurinol

Question 6

Secukinumab is:

Accepted Answer

Anti IL-17

Answer

Anti IL-1

Answer

Anti IL-6

Answer

Anti IL-23

Question 7

What is true about anaphylactoid reactions caused by NSAIDs?

Accepted Answer

COX-2 inhibitors are safe.

Answer

Caused by all NSAIDs.

Answer

Related to hypersensitivity reaction.

Answer

Not related to inhibition of COX.

Question 8

Morphine is contraindicated in all of the following conditions except?

Accepted Answer

Pulmonary edema

Answer

Emphysema

Answer

Bronchial asthma

Answer

Head injury

Question 9

Which of the following drugs is NOT used for analgesia in a patient with head injury?

Accepted Answer

Morphine

Answer

NSAIDs

Answer

Rofecoxib

Answer

Acetaminophen

Question 10

Which of the following is a selective COX-2 inhibitor?

Accepted Answer

Celecoxib

Answer

Indomethacin

Answer

Naproxen

Answer

All of the above

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?